Amarin sues FDA over off-label use discussions with physicians

Amarin Pharma sued the FDA on May 7 and declared it had the constitutional right to discuss off-label use of drugs with doctors, the New York Times reports.

Attorneys said this was the first time they can remember a pharmaceutical manufacturer filing a pre-emptive lawsuit against the FDA over a free-speech issue.